|
|
| SPEAKER |
| Dr. Mark Lewis |
| Reader in Cell Biology & Director of Research Operations |
|
UCL Eastman Dental Institute
|
|
|
|
MEETING
|
|
March 2009 |
|
| BIOGRAPHY |
Mark Lewis is Director of Research Operations and Reader at the UCL Eastman Dental Institute in London. In 1994, Mark obtained his PhD in Biochemistry and Cell Biology from the University of London. During this period, Mark started to develop his specialist interest in cells and their environment. This research interest has greatly expanded through his 16 years at UCL where he continues to advance the field of regeneration and repair of soft tissues including skeletal muscle and dermis with special reference to the oral/craniofacial environment. His Group?s research falls within the remit of the Tissue Engineering Division and aims to both understand the underlying biology of regeneration and repair events and to generate approaches for potential clinical intervention. The particular focus is in the regeneration and repair of soft tissues involving the cellular response of myoblasts and fibroblasts and their interactions with their environment. This includes other cells (e.g. osteoblasts, keratinocytes), extracellular matrix and, highly topically, bioactive, biodegradable and biocompatible scaffolds for tissue engineering applications.
In addition to running a very successful research programme at the UCL Eastman Dental Institute, Mark has for a number of years acted as a Scientific Consultant to a number of commercial regen companies including Isolagen Europe Ltd. In what is a rapidly changing regulatory landscape, Mark?s experiences with Isolagen have ranged from dealing with the media to suggested changes to their processes through to UCL projects funded by the company. Mark?s talk will focus on his experience of translating basic science into therapies for routine clinical practicing drawing on his experiences at UCL as well as in particular in his consultancy capacity to companies such as Isolagen.
|
| TALK |
|
Cell Therapy: View from the front line ? an academic experience
|
| DESCRIPTION |
|
Isolagen Inc, founded in 1995 and located in Houston, Texas, has become an emerging force in regenerative medicine by specialising in the development and commercialisation of its autologous cellular system technology. The 'Isolagen Process' represents a unique breakthrough in autologous cell therapy technology including potential applications in a number of areas such as cosmetic dermatology, cosmetic surgery, periodontal disease, and reconstructive dentistry. To date well in excess of 8,500 patients have been treated with Isolagen produced autologous cell therapies.
|
|
